Loading
A phase 2 trial of Catumaxomab in Ovarian cancer, run by AGO Study Group, completed.
Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients is a phase 2 interventional study registered as NCT00189345 by AGO Study Group, with 44 participants recorded, started 2004-05. Interventions recorded: anti-EpCAM x anti-CD3 (removab). Conditions recorded: Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms.
Linked to the drug Catumaxomab because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Catumaxomab, Ovarian cancer and the tag pipeline.
Shares Catumaxomab, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares AGO Study Group, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/